QNCX · Company research
Quince Therapeutics, Inc. (QNCX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Quince Therapeutics, Inc. (QNCX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Preferred shares underpin a passive stake above 5% in Quince Therapeutics (QNCX). - Stock Titan | Preferred shares underpin a passive stake above 5% in Quince Therapeutics (QNCX). Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Warrants for 456,427 shares are excluded from a reported stake in Quince Therapeutics (QNCX). - Stock Titan | Warrants for 456,427 shares are excluded from a reported stake in Quince Therapeutics (QNCX). Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 - ad-hoc-news.de | Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 14, 2026 | neutral | 0 | 0.6 |
| IRulya Therapeutics (Nasdaq:IRLA) - Stock Analysis - Simply Wall Street | IRulya Therapeutics (Nasdaq:IRLA) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Quince Relaunches as IRulya Therapeutics with New Leadership - The Globe and Mail | Quince Relaunches as IRulya Therapeutics with New Leadership The Globe and Mail | View source ↗ | The Globe and Mail | Oct 10, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease | Quince Therapeutics has rebranded to IRulya Therapeutics and will trade on Nasdaq under ticker 'IRLA' starting October 12, 2026. The company is focused on advancing LAM-001, an inhaled rapamycin formulation for pulmonary diseases including PH-ILD, BOS, and SAPH. New leadership has been appointed including CEO Brigette Roberts, M.D., and the company has a cash balance of $116 million expected to fund operations through end of 2028. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease | Quince Therapeutics has rebranded to IRulya Therapeutics and will trade on Nasdaq under ticker 'IRLA' starting October 12, 2026. The company is focused on advancing LAM-001, an inhaled rapamycin formulation for pulmonary diseases including PH-ILD, BOS, and SAPH. New leadership has been appointed including CEO Brigette Roberts, M.D., and the company has a cash balance of $116 million expected to fund operations through end of 2028. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan | A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Quince Shareholders Approve New Equity and Stock Plans - The Globe and Mail | Quince Shareholders Approve New Equity and Stock Plans The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| (QNCX) and the Role of Price-Sensitive Allocations - Stock Traders Daily | (QNCX) and the Role of Price-Sensitive Allocations Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 28, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) | QNCX EFFECT - Stock Titan | Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) | QNCX EFFECT Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 - TradingView | QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 TradingView | View source ↗ | TradingView | Aug 14, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance | Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy Yahoo Finance | View source ↗ | Yahoo Finance | Jun 2, 2026 | neutral | 0 | 0.6 |
| QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade | QNCX Stock Slides As Traders React To Volatile Price Action StocksToTrade | View source ↗ | StocksToTrade | May 18, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha | Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18 Seeking Alpha | View source ↗ | Seeking Alpha | May 18, 2026 | neutral | 0 | 0.6 |
| QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings | QNCX Stock News - Quiver Quantitative | QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings | QNCX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | May 11, 2026 | neutral | 0 | 0.6 |
| Curious about the most active stocks on Wednesday? - ChartMill | Curious about the most active stocks on Wednesday? ChartMill | View source ↗ | ChartMill | Apr 8, 2026 | neutral | 0 | 0.6 |
| $QNCX stock is down 12% today. Here's what we see in our data. - Quiver Quantitative | $QNCX stock is down 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 6, 2026 | neutral | 0 | 0.6 |
| QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger - Stocktwits | QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger Stocktwits | View source ↗ | Stocktwits | Mar 30, 2026 | neutral | 0 | 0.6 |
| Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com | Quince Therapeutics stock plummets after revealing strategic alternatives Investing.com | View source ↗ | Investing.com | Feb 12, 2026 | neutral | 0 | 0.6 |
| Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits | Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? Stocktwits | View source ↗ | Stocktwits | Feb 10, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.